- Home
- News
- Topics
- FDA Week
- Inside CMS
- Inside Drug Pricing
- Health Exchange Alert
- Inside TeleHealth
- About Us
Mercury in Plasma-Derived Products
[Thimerosal in Vaccines]
This is the second update of the original posting. The Ortho-Clinical Diagnostics product, Rho (D) Immune Globulin (Human), RhoGAM, was originally listed as containing 9 milligrams of mercury in each dose. The first update indicated that the correct amount is 9 micrograms. In this second update additional information is included regarding different doses of RhoGAM, and the mercury content of other Rho (D) Immune Globulin products is described.
/index.php?option=com_iwpfile&file=/dir_01/he2002_2206.pdf
/index.php?option=com_iwpfile&file=/dir_01/he2002_2205.pdf
/index.php?option=com_iwpfile&file=/dir_01/he2002_2204.pdf
od Transfusions
Information about West Nile Virus and Blood Safety
Background
The ongoing outbreak of West Nile virus (WNV) infections in the United States has raised concern that WNV could be transmitted through blood transfusion. No cases of WNV attributed to transfusion of blood or blood products have been reported to date in the United States or elsewhere. Available data indicate a theoretical, albeit small, risk of WNV transmission from transfusion of blood.
FDA Blood Safety Provisions
Donor Deferral
nd 2012
CONGRESSIONAL BUDGET OFFICE
PAY-AS-YOU-GO ESTIMATE
July 8, 2002
H.R. 3448
Public Health Security and Bioterrorism Preparedness and Response Act of 2002
As cleared by the Congress on May 23, 2002, with corrections adopted in S. Con. Res. 117 on June 4, 2002, and signed by the President on June 12, 2002
SUMMARY
ys
[Federal Register: August 19, 2002 (Volume 67, Number 160)]
[Notices]
[Page 53805-53806]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr19au02-71]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 02N-0354]
Agency Emergency Processing under OMB Review; The Evaluation of Long-Term Antibiotic Drug Therapy for Persons Involved in Anthrax Remediation Activities